FDA: Entacapone Not Associated With Increased Prostate Cancer Risk
The FDA has concluded that the use of entacapone to treat Parkinson disease (PD) does not increase the risk of developing prostate cancer.
Prostate Cancer
Prostate Cancer News & Features
Adjuvant Radiotherapy Cuts Prostate Cancer Recurrence Risk
Adjuvant radiotherapy following radical prostatectomy (RP) for PCa with positive margins or extracapsular extension prolongs biochemical recurrence-free survival compared with RP alone, a study found.
Quality of Life Outcomes Comparable Regardless of Treatment With HRT or CRT for Low-Risk Prostate Cancer
Hypofractionated radiotherapy (HRT) offers quality-of-life outcomes similar to conventional radiation therapy for men with low-risk prostate cancer, according to recently published results of a phase 3 randomized study. HRT offers a less expensive and more convenient treatment option for some patients, and in light of the new findings about quality of life, should be considered…
FDA Clears Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer
In the phase 3 ARAMIS trial, darolutamide, a nonsteroidal androgen receptor inhibitor, significantly delayed development of metastasis in men with nonmetastatic castration-resistant prostate cancer.
Prostate Cancer ADT Raises Dementia Risk, Study Finds
Androgen deprivation therapy for prostate cancer is associated with a significant 20% increased risk of dementia and 14% increased risk of Alzheimer’s disease, a study found.
Want to read more?
Please login or register first to view this content.
Next post in Prostate Cancer
